Posts Tagged ‘glucose control’

September 22nd, 2014

Selections from Richard Lehman’s Literature Review: September 22nd

This week’s topics include one-year outcomes after thrombus aspiration for MI, the evaluation and treatment of older patients with hypercholesterolemia, and more.

July 3rd, 2014

Sitagliptin Associated with Increase in Heart Failure Hospitalizations

The cardiovascular effects of drugs used for glucose control in patients with diabetes have been a subject of controversy for many years now. More recently, attention has started to focus specifically on the risk for heart failure (HF). Now, an observational study will likely raise new questions about the dipeptidyl peptidase (DPP)-4 inhibitor sitagliptin (Januvia, Merck). In […]

May 14th, 2014

Informed Interpretation of the 20-Year Results of the DIGAMI Trial

Darren McGuire gives us his perspective on the DIGAMI trial results.

June 29th, 2012

Linagliptin and Glimepiride Compared in Type 2 Diabetes

Sulfonylureas are often added to metformin to improve glycemic control, but at the known risk of increasing hypoglycemia and weight gain. In a report published in the Lancet, more than 1,500 patients with type 2 diabetes taking metformin were randomized to the addition of either linagliptin, a dipeptidyl peptidase-4 inhibitor, or glimepiride, a sulfonylurea. After two years, the trial […]

June 9th, 2012

Transient Glucose Regulation Helps Prevent Progression to Diabetes in Prediabetics

Prediabetics — people with impaired fasting glucose or impaired glucose tolerance — can reduce their high risk for progressing to diabetes if they achieve even a transient return to normal glucose regulation, according to results of the Diabetes Prevention Program Outcomes Study (DPPOS), presented at the American Diabetes Association meeting and published simultaneously online in the Lancet. Leigh Perreault […]

March 3rd, 2011

5-Year Followup of ACCORD: Still No Support For Intensive Glucose Lowering

Long-term followup of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial has once again failed to support routine intensive glucose lowering in high-risk type 2 diabetics. In 2008, as reported in the New England Journal of Medicine, the intensive glucose-lowering regimen (target glycated hemoglobin level of <6%) was terminated early after an increase in mortality was […]

October 8th, 2010

Analysis of ADVANCE Explores Role of Hypoglycemia

A new analysis of the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation) trial sheds light on the role of hypoglycemia in recent trials of glucose control. In a paper in the New England Journal of Medicine, the ADVANCE investigators report that 2.1% of 11,140 patients with type 2 diabetes […]